James Hardie Industries (JHX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jul, 2026Executive summary
Annual meeting scheduled for August 20, 2026, in Dublin, with voting available online or in person.
Proxy materials, annual report, and statutory accounts are accessible electronically or by request.
Shareholders are encouraged to consent to electronic delivery to support environmental initiatives.
Voting matters and shareholder proposals
Proposals include re-election/election of directors, say-on-pay, CEO equity grant, director equity plan, and amendments to articles.
Board recommends voting FOR all director nominees, 1-year frequency for say-on-pay, and FOR all other proposals except Proposal 6 (no recommendation).
Proposal 6 seeks to increase the non-executive director fee pool.
Shareholders will also ratify the external auditor and authorize auditor compensation for FY 2027.
Amendments to apply classified board provisions consistently to all directors are up for approval.
Board of directors and corporate governance
Nominees for re-election: Nigel Stein and Renee Peterson; new nominee: Rob Sindel.
Proposal to amend articles for consistent application of classified board provisions.
Latest events from James Hardie Industries
- Board seeks approval for revised executive and director pay structures aligned with shareholder feedback.JHX
Proxy filing - Redesigned CEO equity grant and improved compensation structure headline annual meeting proposals.JHX
Proxy filing - Net sales and adjusted EBITDA exceeded guidance, driving a raised FY27 outlook and strong cash flow.JHX
Q1 2027 - Shareholders will vote on board, pay, auditor, and governance changes after a year of major transformation.JHX
Proxy filing - Major acquisition, board refresh, and executive pay overhaul highlight FY26 governance and strategy.JHX
Proxy filing - AZEK acquisition and synergy gains drove strong sales and EBITDA growth, with FY27 targets raised.JHX
Q4 2026 - Net sales up 30% to $1.24B, with higher EBITDA and raised FY26 guidance amid synergy progress.JHX
Q3 2026 - Q2 FY26 sales jumped 34% on AZEK deal; margins fell, but FY26 outlook and synergies improved.JHX
Q2 2026 - Record Q1 EBITDA and 4% sales growth achieved; FY25 guidance reaffirmed amid market headwinds.JHX
Q1 2025